Goto

Collaborating Authors

EpigenCare uses epigenetics, blockchain and artificial intelligence innovation

#artificialintelligence

EpigenCare, a personalised skin care technology startup, announced on 4th April that it had won the Johnson & Johnson Innovation competition for cutting-edge skin care technologies. Johnson & Johnson, the multinational consumer packaged goods manufacturing company, launched its innovation arm to identify progressive and forward-thinking digital beauty solutions. With a particular focus on personalisation items, it was set up to help consumers make better-informed decisions when it comes to their skin care routines. These leading trends in science and technology come at time, as Lee stated, when consumers are unaware of the true efficacy of skin care products, and when static genetic variants in current personal genomic tests cannot be modified by product ingredients. Focusing on epigenetics, blockchain and AI, Lee discussed an epigenetics-related solution that works by identifying a gene function's level of activity or inactivity.


How Artificial Intelligence Is Accelerating Life Sciences

#artificialintelligence

The drug development lifecycle is long and fraught with heavy risk -- it takes a staggering 10 – 15 years on average, with ultimately only 12 percent of drugs in clinical trials gaining approval by the U.S. Food and Drug Administration (FDA) [1]. To put this in perspective, 22.7 percent of all global research and development spending in 2017 was in the healthcare industry, second only to 23.1 percent spent in the computing and electronics industry, yet the product lifecycle is longer, and costs are much higher [2]. For example, the original iPhone took two and a half years to develop from concept to launch, and an estimated $150 million spent in research and development [3]. In contrast, the average cost of new drug and biologics is $2.87 billion when factoring in the post-approval research and development costs, according to figures released in May 2016 by The Tufts Center for the Study of Drug development (CSDD) [4]. For pharmaceutical companies that have launched more than four drugs, the median cost is closer to a staggering $5.3 billion according to analysis by industry expert Matthew Herper of Forbes [5].


How Artificial Intelligence Is Accelerating Life Sciences

#artificialintelligence

The drug development lifecycle is long and fraught with heavy risk -- it takes a staggering 10 – 15 years on average, with ultimately only 12 percent of drugs in clinical trials gaining approval by the U.S. Food and Drug Administration (FDA) [1]. To put this in perspective, 22.7 percent of all global research and development spending in 2017 was in the healthcare industry, second only to 23.1 percent spent in the computing and electronics industry, yet the product lifecycle and cost are much higher [2]. For example, the original iPhone took two and a half years to develop from concept to launch, and an estimated $150 million spent in research and development [3]. In contrast, the average cost of new drug and biologics is $2.87 billion when factoring in the post-approval research and development costs, according to figures released in May 2016 by The Tufts Center for the Study of Drug development (CSDD) [4]. For pharmaceutical companies that have launched more than four drugs, the median cost is closer to a staggering $5.3 billion according to analysis by industry expert Matthew Herper of Forbes [5].


Toronto's thriving AI ecosystem serves as a model for the world

#artificialintelligence

While you were looking the other way, Toronto humbly produced some of the globe's top artificial intelligence and deep learning experts, companies, and innovations. Now is the time for the city to stand up tall and loudly proclaim what local folks already know: Toronto is at the center of AI innovation and its real-world applications. The city is home to world-class academic institutions like the University of Toronto and nearby to the University of Waterloo, both of which constantly churn out bright computer and data scientists, engineers, and developers building next-generation AI technologies. These institutions are world leaders in scientific research, creating an ecosystem ripe with opportunities for novel applications for AI, particularly in the fields of health and life sciences. My own company actively recruits staff from both schools.


Toronto's thriving AI ecosystem serves as a model for the world

#artificialintelligence

While you were looking the other way, Toronto humbly produced some of the globe's top artificial intelligence and deep learning experts, companies, and innovations. Now is the time for the city to stand up tall and loudly proclaim what local folks already know: Toronto is at the center of AI innovation and its real-world applications.